Immune globulin (human) is under clinical development by Chengdu Rongsheng Pharmaceutical and currently in Phase III for Primary Immune Deficiency (PID). According to GlobalData, Phase III drugs for Primary Immune Deficiency (PID) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Immune globulin (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Immune globulin (human) overview
Immune globulin (IVIG) is under development for the treatment of primary immune thrombocytopenia and primary immunodeficiency (PID). The drug candidate is administered by intravenous and subcutaneous route.
Chengdu Rongsheng Pharmaceutical overview
Chengdu Rongsheng Pharmaceutical is engaged in the manufacture of pharmaceutical preparations and is specialised in processing of chemical substances combined to a pure drug substance to produce a final medicinal product. The company is Headquartered in China.
For a complete picture of Immune globulin (human)’s drug-specific PTSR and LoA scores, buy the report here.